Investigation for New Discovery of Biomarkers
BioFIND is a two-year observational clinical study designed to discover and verify biomarkers of Parkinson's disease (PD). The study is carried out at six academic sites in the United States and began recruitment in 2012. BioFIND is collecting clinical data and biospecimens, including blood and cerebrospinal fluid (CSF), in a population of 120 well-defined, moderately advanced PD subjects and 120 healthy controls.
BioFIND will follow standardized data acquisition protocols to ensure that tests and assessments conducted at multiple sites can be pooled. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson's database and biorepository, which will be available to the scientific community to conduct research on novel PD biomarkers. The study aims to complement PPMI to produce the most comprehensive and long-ranging dataset available for biomarker discovery work throughout the PD community.
Only with collaborative efforts like BioFIND can we efficiently discover and verify biomarker candidates for PD. This study is sponsored by The Michael J. Fox Foundation for Parkinson's Research with support from the National Institute of Neurological Disorders and Stroke (NINDS).
BioFIND Samples are now available for request!
While study recruitment is ongoing, clinical data and biospecimen from BioFIND are now available for request. Clinical data from BioFIND is hosted at LONI. Please visit the study site at LONI to apply for expedited access to available data and receive updates when additional data become available. To request access to available BioFIND samples, please complete and submit a letter of intent to the Access Data and Biospecimens program.
Available Biospecimens and Data*
|Clinical Data||Whole Blood Pellet||Plasma||DNA||RNA||CSF|
*Available resources as of January 2, 2014. Numbers refer to submission from unique individuals. Typical submissions include: clinical data, 2 whole blood pellets, 12 ml plasma from whole blood, 8.5 ml whole blood for DNA extraction, 5 ml whole blood for RNA extraction, 10 ml cerebrospinal fluid.
Recruitment is ongoing and sites continue to collect samples and clinical data. The next cut of data and samples will be released on April 7, 2014.